The Burnet Vaccine Initiative (BVI) develops novel vaccine candidates and strategies for high lasting protection against some of the world’s most devastating pathogens.
Burnet is working on ways to slow the detrimental biological process of 'inflammageing', the build-up of low-grade inflammation in the body, increasing the risk of age-related conditions.
Burnet’s Stellabody technology exploits a natural antibody behaviour to facilitate the formation of hexamers. This enhances the action of antibodies and related biologics.
Burnet’s microbiome researchers have significant expertise and unique technical assays and capabilities. We are ready to work with you on your microbiome research and development activities including diagnostic and therapeutic applications.
The Burnet Diagnostics Initiative (BDI) is the culmination of Burnet’s broad-based expertise in addressing the most pressing global health challenges through life sciences and implementation research.
Burnext is a program that will accelerate Burnet’s ability to translate medical research into practical health benefits.
Bringing innovation to market. For nearly 40 years, Burnet has worked to address the most pressing global health challenges and ensure no one is left behind.